Anzeige
Mehr »
Sonntag, 12.07.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0EAT9 | ISIN: BE0003818359 | Ticker-Symbol: GXE
Tradegate
10.07.26 | 10:56
26,680 Euro
+0,98 % +0,260
Branche
Biotechnologie
Aktienmarkt
BEL Mid
AMX
1-Jahres-Chart
LAKEFRONT BIOTHERAPEUTICS NV Chart 1 Jahr
5-Tage-Chart
LAKEFRONT BIOTHERAPEUTICS NV 5-Tage-Chart
RealtimeGeldBriefZeit
26,28026,46011.07.
26,32026,50010.07.

Aktuelle News zur LAKEFRONT BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrLakefront Biotherapeutics stock coverage resumed at Equalweight by Morgan Stanley2
FrMorgan Stanley nimmt Bewertung von Lakefront Biotherapeutics mit "Equalweight" wieder auf2
DiLakefront Biotherapeutics NV - 6-K, Report of foreign issuer2
29.06.Lakefront Biotherapeutics: Lakefront Receives Transparency Notification from Madison Avenue Partners822Mechelen, Belgium; June 29, 2026, 22.01 CET; regulated information - Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Madison Avenue Partners. Pursuant...
► Artikel lesen
24.06.Lakefront Biotherapeutics NV - 6-K, Report of foreign issuer1
16.06.Lakefront Biotherapeutics NV - 6-K, Report of foreign issuer1
LAKEFRONT BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
09.06.Lakefront BioTherapeutics launches €50M share buyback program1
09.06.Lakefront Biotherapeutics: Lakefront Announces Initiation of €50 Million Stock Repurchase Program490Mechelen, Belgium; June 9, 2026, 22:01 CET; regulated information - Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced the launch of a share repurchase program (the "Program")...
► Artikel lesen
09.06.Gilead And Lakefront Biotherapeutics Complete Ouro Medicines Acquisition To Advance Autoimmune Disease Pipeline5
08.06.Lakefront Biotherapeutics: Lakefront Appoints Eric Hedrick, MD, as Chief Medical Officer262Mechelen, Belgium; June 8, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that Eric Hedrick, MD has been appointed Chief Medical Officer. This expanded leadership...
► Artikel lesen
08.06.Gilead Sciences und Lakefront Biotherapeutics schließen Übernahme von Ouro Medicines ab und bauen damit ihre Entzündungspipeline weiter aus4
05.06.Gilead Sciences, Lakefront Biotherapeutics Acquire Ouro Medicines9
05.06.Lakefront Biotherapeutics NV - 6-K, Report of foreign issuer2
04.06.Gilead, Lakefront Biotherapeutics complete Ouro Medicines acquisition6
04.06.Gilead and Lakefront Biotherapeutics complete Ouro Medicines acquisition5
04.06.Gilead Sciences, Inc.: Gilead Sciences and Lakefront Biotherapeutics Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline830- Companies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases - Gilead Sciences, Inc. (Nasdaq: GILD) and Lakefront...
► Artikel lesen
27.05.Lakefront Biotherapeutics NV - 6-K, Report of foreign issuer1
26.05.Lakefront Biotherapeutics: Lakefront Receives Transparency Notification from Bank of America767Mechelen, Belgium; May 26, 2026, 22.01 CET; regulated information - Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America. Pursuant to...
► Artikel lesen
13.05.Galapagos NV: Namensänderung in Lakefront Biotherapeutics NV15
07.05.Galapagos Q1 2026 presentation: Ouro deal, rebranding highlight transformation16
Weiter >>
73 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1